Acadia Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
18.75
+0.61 (3.36%)
At close: Nov 13, 2026, 4:00 PM EST
18.75
0.00 (0.00%)
Pre-market: Nov 16, 2026, 4:30 AM EST
Acadia Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, Acadia Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $30.32. The average 1-year stock price forecast is 61.71% higher than the current stock price, while the lowest is $16 (-14.67%) and the highest is $38 (+102.67%).
Price Target: $30.32 (+61.71%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Acadia Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 11 | 10 | 10 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 21 | 21 | 21 | 20 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $28 → $24 | Hold | Maintains | $28 → $24 | +28.00% | Nov 13, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $31 | Buy | Maintains | $31 | +65.33% | Nov 11, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $34 | Buy | Maintains | $34 | +81.33% | Nov 10, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $36 → $38 | Buy | Reiterates | $36 → $38 | +102.67% | Nov 6, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Maintains $27 | Buy | Maintains | $27 | +44.00% | Nov 5, 2026 |
Financial Forecast
Revenue This Year
1.28B
from 1.07B
Increased by 19.52%
Revenue Next Year
1.45B
from 1.28B
Increased by 13.36%
EPS This Year
0.76
from 0.83
Decreased by -8.21%
EPS Next Year
1.08
from 0.76
Increased by 41.66%
EPS and Forward PE are based on non-GAAP adjusted numbers.